TAFA chemokine like family member 3Genealiases: FAM19A3 · TAFA-3
Q-omics provides the consensus-scored TAFA3 profile across patient tissues and cancer cell-line models. TAFA3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAFA3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TAFA3 RNA expression shows 13,022 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where TAFA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAFA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAFA3 survival associations across molecular data types. TAFA3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAFA3 RNA expression–survival associations across cancer types. High TAFA3 expression shows unfavorable associations in KIRC, STAD, ACC, LGG, LIHC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAFA3 RNA expression.
This table summarizes TAFA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TAFA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAFA3 shows lower tumor expression in THCA and BRCA and higher tumor expression in LUSC, BLCA, LUAD and KIRP. The THCA box plot shows higher TAFA3 RNA expression in normal versus tumor tissue (log2 FC = −1.461, t-test p < 0.001).
This table shows molecular features associated with TAFA3 in patient tissues and cancer cell lines. In patient samples, TAFA3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TAFA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
